Ian Hardy, PhD, MBA
Ian Hardy has 30+ Chemistry, Manufacturing and Controls experience from late phase discovery to commercialization across a range of therapeutic modalities including small molecules, monoclonal antibodies and bi-specifics. Ian spent close to 20 years with Glaxo/GlaxoWellcome, Astra Zeneca and Merck focusing on drug product development across a range of administration routes including oral (immediate release/modified release and poorly water-soluble compounds), topical, inhalation, nasal and injectables. After large pharma, Ian led CMC activities at a number of biotech companies including Lycera with responsibilities for CMC strategy and execution across drug substance, drug product and clinical supply chain. After Lycera, Ian led CMC for Deerfield Management a healthcare investment group supporting investment diligence, early stage venture companies and building out an internal development team and portfolio of assets. Ian founded PractiClarity Consulting LLC to provide CMC consulting services and fractional executive support to biotech companies and healthcare investment firms.